We have observed
7 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after March 23, 2014).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Pharmaceutical composition capable for the incorporation Febuxostat in the crystalline modifications F10, II, G and A
Immediate release dosage forms of Atomoxetine
OPTIMIZED SYNTHESIS OF PREGABALIN AND 4-AMINO BUTANOIC ACID USING AN IMPROVED PRODUCTION METHOD OF CONJUGATED NITROALKENES
FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION
NON-CRYSTALLINE FORM OF PALBOCICLIB
METHOD FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS COMPRISING GADOLINIUM CHELATE COMPLEXES WITH REDUCED TOXIC CONTAMINATION
FIXED DOSED PHARMACEUTICAL COMPOSITION COMPRISING AMIODIPINE, CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION.